Angelman's syndrome
RecruitingA Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome
A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome
- Disease:Angelman's syndrome
- Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
Italy- Participants:0–17 years · 18–64 years
- Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
- Sponsor:Ionis Pharmaceuticals Inc.











